NO20052009L - Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome - Google Patents

Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Info

Publication number
NO20052009L
NO20052009L NO20052009A NO20052009A NO20052009L NO 20052009 L NO20052009 L NO 20052009L NO 20052009 A NO20052009 A NO 20052009A NO 20052009 A NO20052009 A NO 20052009A NO 20052009 L NO20052009 L NO 20052009L
Authority
NO
Norway
Prior art keywords
treatment
myelodysplastic syndrome
acute leukemia
combination therapy
pharmaceutical combinations
Prior art date
Application number
NO20052009A
Other languages
Norwegian (no)
Other versions
NO20052009D0 (en
Inventor
Jay Marshall Feingold
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20052009D0 publication Critical patent/NO20052009D0/en
Publication of NO20052009L publication Critical patent/NO20052009L/en

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives fremgangsmåter for behandling og farmasøytiske kombinasjoner for behandlingen av akutt leukemi, så som akutt myelogen leukemi og myelodysplastisk syndrom. Fremgangsmåtene og de farmasøytiske kombinasjonene benytter et anti-CD33 cytotoksisk konjugat i kombinasjon med minst én forbindelse valgt fra gruppen bestående av et antracyklin og en pyrimidin- eller purin-nukleosidanalog. Foretrukne fremgangsmåter for behandling og farmasøytiske kombinasjoner benytter gemtuzumab ozogamicin, daunorubicin og cytarabin.Methods of treatment and pharmaceutical combinations for the treatment of acute leukemia, such as acute myelogenous leukemia and myelodysplastic syndrome, are described. The methods and pharmaceutical combinations employ an anti-CD33 cytotoxic conjugate in combination with at least one compound selected from the group consisting of an anthracycline and a pyrimidine or purine nucleoside analogue. Preferred methods of treatment and pharmaceutical combinations utilize gemtuzumab ozogamicin, daunorubicin and cytarabine.

NO20052009A 2002-11-06 2005-04-25 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome NO20052009L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
NO20052009D0 NO20052009D0 (en) 2005-04-25
NO20052009L true NO20052009L (en) 2005-06-27

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052009A NO20052009L (en) 2002-11-06 2005-04-25 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Country Status (10)

Country Link
EP (1) EP1575582A4 (en)
JP (1) JP2006508119A (en)
CN (1) CN1720044A (en)
AU (2) AU2002348178A1 (en)
BR (1) BR0215935A (en)
CA (1) CA2504611A1 (en)
CR (1) CR7804A (en)
MX (1) MXPA05004711A (en)
NO (1) NO20052009L (en)
WO (1) WO2004043461A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
KR20080030659A (en) * 2005-07-06 2008-04-04 카니사 파마슈티컬즈, 인크. Treatment of cancer patients using calicheamicin-antibody conjugates in combination with josquidar
ES2371085T3 (en) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. USE OF AMATOXIN OR FALOTOXIN CONJUGATES WITH MACROMOLECULES FOR TUMOR THERAPY AND INFLAMMATION.
CN1994293A (en) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 Application of Oridonin A in Pharmaceuticals
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
PL3300601T3 (en) * 2007-02-16 2022-05-02 Rotalec Ip Holdings Llc Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders
EP2249831A2 (en) * 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US20110159507A1 (en) 2008-08-29 2011-06-30 School Juridical Person The Kitasato Institute Method for detecting the drug effects of dna methylation-inhibitors
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) * 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
AR112202A1 (en) * 2017-06-22 2019-10-02 Servier Lab COMBINATION OF A MCL-1 INHIBITOR AND A STANDARD CARE TREATMENT FOR HEMATOLOGICAL CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
IL285155B2 (en) * 2019-01-28 2026-01-01 Univ Texas Metal chelator combination therapy for the treatment of cancer
CN110123825B (en) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 Pharmaceutical composition containing demethoxydaunorubicin
WO2022093983A1 (en) * 2020-10-27 2022-05-05 Vor Biopharma, Inc. Compositions and methods for treating hematopoietic malignancy
WO2025214401A1 (en) * 2024-04-12 2025-10-16 四川科伦博泰生物医药股份有限公司 Antibody-drug conjugate, composition, and use thereof and method therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
CA2418014C (en) * 2000-08-08 2014-01-21 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia

Also Published As

Publication number Publication date
WO2004043461A1 (en) 2004-05-27
NO20052009D0 (en) 2005-04-25
CN1720044A (en) 2006-01-11
CR7804A (en) 2008-10-29
CA2504611A1 (en) 2004-05-27
AU2002348178A1 (en) 2004-06-03
BR0215935A (en) 2005-08-09
EP1575582A4 (en) 2009-03-11
EP1575582A1 (en) 2005-09-21
MXPA05004711A (en) 2005-08-03
AU2010201113A1 (en) 2010-04-15
JP2006508119A (en) 2006-03-09

Similar Documents

Publication Publication Date Title
NO20052009L (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2007022073A3 (en) Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
NZ543867A (en) Modified fluorinated nucleoside analogues
CY1113012T1 (en) LIPOSOMIC PHARMACEUTICAL FORMS OF CARBONIC CYLINDER AND CYTIDINE ANALOG
AP2005003211A0 (en) 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
UY29949A1 (en) PHARMACEUTICAL COMPOSITION WITH HIGH INTENSITY EDULCORANT
ES2138969T3 (en) COMBINATION OF ANTIVIRAL NUCLEOSIDES.
BRPI9809791B8 (en) aminoalkyl glucosamine phosphate immuno-effecting compounds and compositions comprising the same
DK0526537T3 (en) 5-benzyl barbiturate derivatives
PL1644392T3 (en) Rapamycin carbohydrate derivatives
UY29954A1 (en) HIGH INTENSITY EDULCORANT COMPOSITION WITH AN ANTI-INFLAMMATORY AGENT AND COMPOSITIONS sweetened with it
DK1412368T3 (en) Sugar derivatives of hydromorphone, dihydromorphine, dihydroisomorphine, their compositions and applications for the treatment or prevention of pain
RS20120201A3 (en) METHODS AND MIXTURES FOR TREATMENT OF VIRAL HEPATITIS C
MX2009012155A (en) A synergistic pharmaceutical combination for the treatment of cancer.
BRPI0503981A (en) low calorie sugar substitute with water-insoluble bulking agent
WO2004028475A3 (en) Glycosylceramide analogues
PT1368041E (en) AQUOSA COMPOSITION OF ANFOTERICINE
BR9908391A (en) Anti-tumor composition containing a synergistically combination of an anthracycline derivative with a camptothecin derivative
WO2008104893A3 (en) Nucleoside derivatives useful for the treatment or prevention of viral infections and methods of use thereof
DK1079840T3 (en) Synergistic preparation of inulin and an anticancer drug for use in the treatment of cancer
HRP20090336T1 (en) ANTI-TUMOR COMBINATIONS CONTAINING A VEGF AND 5-FU LOCK OR ONE OF ITS DERIVATIVES
UA83204C2 (en) Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
EP4464701A4 (en) 1,3-BENZODIOXOL DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION WITH IT
ATE465741T1 (en) 9A-CARBAMOYL-Y-AMINOPROPYL AND 9A-THIOCARBAMOYL-Y-AMINOPROPYL AZALIDES WITH ANTIMALARIA ACTIVITY
RU2005117335A (en) COMBINED THERAPY FOR TREATMENT OF ACUTE LEUKOSIS AND MYELODYSPLASTIC SYNDROME

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application